Rhenman & Partners Asset Management AB Buys 6,750 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Rhenman & Partners Asset Management AB grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 39.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,750 shares of the company’s stock after purchasing an additional 6,750 shares during the quarter. Rhenman & Partners Asset Management AB owned about 0.08% of Krystal Biotech worth $3,721,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KRYS. Wilmington Savings Fund Society FSB bought a new position in Krystal Biotech during the third quarter worth $40,000. Avanza Fonder AB bought a new position in shares of Krystal Biotech in the 4th quarter worth about $119,000. KBC Group NV lifted its stake in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after purchasing an additional 297 shares during the period. Blue Trust Inc. boosted its position in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE grew its stake in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on KRYS shares. Chardan Capital boosted their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $220.00.

Krystal Biotech Stock Performance

KRYS stock opened at $171.30 on Friday. The business has a 50-day simple moving average of $173.27 and a two-hundred day simple moving average of $173.18. The company has a market capitalization of $4.93 billion, a P/E ratio of 57.29 and a beta of 0.75. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.30 earnings per share. As a group, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).